ClinicalTrials.gg
RecruitingNCT06430385Updated Oct 8, 2026

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

A Phase 1/2 interventional study of ION440 and Sham procedure in Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 12 sites in 5 countries. Open to male participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Oct 8, 2026First site in Canada1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
15th of 34
48 · median 32
Started
2024
with 3 others
Phase 1/2
2 of 55
1 open now
Primary completion
2027-09
later than 11 of 20 live
Registered
46th of 55
by date
Lead sponsor
2 of 55
Ionis Pharmaceuticals, Inc.

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 15th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 20 other live ones, and was the 46th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of ION440.

Read the detailed description

This is a phase 1-2 randomized, double-blind, sham-controlled, multiple-ascending dose (MAD) study to evaluate ION440 in pediatric and adult participants with MECP2 Duplication Syndrome (MDS) and will be conducted in two parts. During Part 1 (MAD) (36 weeks), participants will be randomized in a 3:1 ratio to receive ION440 or sham. Individuals who complete Part 1 may enter Part 2, an open label long-term extension study (LTE), where they will receive ION440 for up to approximately 156 weeks. Multiple dose cohorts (Dose A, Dose B, and Dose C) will be evaluated in the study.

All dosing cohorts will be further subdivided by age. Sub cohort A will include participants 8 through 65 years of age, and sub cohort B will include participants 2 through 7 years of age. Dosing cohorts will be enrolled sequentially with sub cohort A initiating prior to sub cohort B.

03

Conditions studied

  • Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Browse trials for

04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria for Part 1:

  1. Males aged ≥ 2 to ≤ 65 years, depending on specific cohort and group, at the time of .

    1. Group A: ≥ 8 to ≤ 65 years old
    2. Group B: 2 to 7 years old, inclusive
  2. Participant has at least one parent or caregiver ≥ 18 years old capable of providing informed consent and able to comply with all study requirements and activities.
  3. Participant has a documented diagnosis of MDS with genetic confirmation of MECP2 duplication.
  4. Is currently receiving stable doses of concomitant medications for at least 1 month prior to screening.
  5. Able to complete all study procedures, measurements and visits to support primary and secondary endpoints, in the opinion of the Investigator.

Key Exclusion criteria for Part 1:

  1. Documented diagnosis of severe MECP2 duplications including terminal duplication and/or translocation or MECP2 triplication OR clinical features associated with severe variant structure including (a) onset of seizures prior to age 5 (for those aged 5 and above at signing of ICF), (b) oxygen dependence, (c) microcephaly, IF MECP2 genetic structure information is unavailable.
  2. vital sign or abnormality at Screening
  3. Known brain or spinal disease that would interfere with the LP procedure, or CSF circulation or presence of other factors would affect the safety of the LP procedure.
  4. Has any concomitant disease or condition or circumstance, or any finding at Screening that, in the opinion of the Investigator, makes the participant unsuitable for enrollment or that could interfere with the conduct of the study or that would pose an unacceptable risk to the participant in this study.
  5. Treatment with an drug, biological agent, or device within 30 days of Screening, or 5 half-lives of investigational agent, whichever is longer.
  6. Previous treatment with an oligonucleotide (including siRNA) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received (this exclusion does not apply to vaccines - both mRNA and viral vector vaccines are allowed including COVID-19). For centrally administered ASOs, a minimum of 12 months is required irrespective of the number of doses received.
  7. Currently enrolled in a clinical trial of an investigational agent or device or has used any investigational agent or device within 5 half-lives of investigational agent, whichever is longer.
  8. Has a history of gene therapy or cell transplantation or any other experimental brain surgery.
  9. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Baseline (Day 1).
  10. Has experienced Status Epilepticus in the past 6 months.

Key Inclusion criteria for Part 2:

  1. Participants in ION440-CS1, Part 1/MAD who received at least one dose of Study Drug /Sham in Part 1/MAD, missed no more than 1 study visit, and attended the Follow Up visit (Visit 6).
  2. All inclusion criteria in Part 1/MAD apply (participants will not be required to undergo new Screening bloodwork).

Key Exclusion criteria for Part 2:

1. Has developed any concomitant disease (e.g., gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or circumstance, or any finding during Part 1/MAD that, in the opinion of the Investigator, makes the participant unsuitable for continued treatment (e.g., could interfere with the conduct of the study or that would pose an unacceptable risk to the participant in this study).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1: ION440 Dose A

    Participants will receive ION440 intrathecally at Dose A during Part 1/MAD, followed by ION440 Dose A during Part 2/LTE.

    Drug: ION440

  • Experimental
    Cohort 2: ION440 Dose B

    Participants will receive ION440 intrathecally at Dose B during Part 1/MAD, followed by ION440 Dose B during Part 2/LTE.

    Drug: ION440

  • Experimental
    Cohort 3: ION440 Dose C

    Participants will receive ION440 intrathecally at Dose C during Part 1/MAD, followed by ION440 Dose C during Part 2/LTE.

    Drug: ION440

  • Sham comparator
    Sham Procedure

    During the Part 1/MAD period, a lumbar procedure (LP) will be performed at the same frequency as ION440 administration. Participants will not receive ITB injections during this period. It will be followed by the open-label Part 2/LTE period, where participants will receive ION440 at the same dose as their enrolled cohort (e.g. Dose A, Dose B or Dose C).

    Procedure: Sham procedure

Interventions

  • DrugION440

    ION440 will be administered by intrathecal bolus (ITB) injection.

  • ProcedureSham procedure

    An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 36 weeks

  2. Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to approximately 36 weeks

  3. Part 1: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination Findings

    Time frame: Baseline up to approximately 36 weeks

  4. Part 1: Number of Participants With Clinically Significant Change from Baseline in Laboratory Assessments

    Time frame: Baseline up to approximately 36 weeks

  5. Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

    Time frame: Baseline up to approximately 36 weeks

  6. Part 2: Number of Participants With TEAEs

    Time frame: Up to approximately 192 weeks

  7. Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to approximately 192 weeks

  8. Part 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination Findings

    Time frame: Baseline up to approximately 192 weeks

  9. Part 2: Number of Participants With Clinically Significant Change from Baseline in Laboratory Assessments

    Time frame: Baseline up to approximately 192 weeks

  10. Part 2: Number of Participants With Clinically Significant Change From Baseline in ECG

    Time frame: Baseline up to approximately 192 weeks

Secondary outcomes

  1. Part 1: Maximum Observed Concentration (Cmax) of ION440 in Plasma

    Time frame: Pre-dose and at multiple points post-dose up to Week 36

  2. Part 1: Area Under the Concentration-time Curve (AUC) of ION440 in Plasma

    Time frame: Pre-dose and at multiple points post-dose up to Week 36

  3. Part 1: Plasma Terminal Elimination Half-life (t½) of ION440

    Time frame: Pre-dose and at multiple points post-dose up to Week 36

  4. Part 1: Trough Concentration (Ctrough) of ION440 in Plasma and CSF

    Time frame: Pre-dose and at multiple points post-dose up to Week 36

  5. Part 1: Plasma Concentration of ION440

    Time frame: Pre-dose and at multiple points post-dose up to Week 36

  6. Part 2: Trough Concentration (Ctrough) of ION440 in Plasma and CSF

    Time frame: Up to approximately 192 weeks

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 28, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Apr 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Canada
Show site
  • British Columbia Children's Hospital · Vancouver, Canada
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added — first site in Canada
    Show site
    • British Columbia Children's Hospital · Vancouver, Canada
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06430385
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Oct 21, 2024
Primary completion
Sep 2027 (estimated)
Completion
Apr 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Ionis Pharmaceuticals
Contact
IonisMECP2study@clinicaltrialmedia.com
(844) 779-1497

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion